Results 261 to 270 of about 336,273 (367)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Spin Balance Over Janus Ir-Co Magnetic Atoms for Efficient Acidic Water Oxidation. [PDF]

Nanomicro Lett
Li N, Cheng W, Liu Y, Liu R, Feng S, Wang H, Lv L, Liu C, Ma J, Wang C, Yan W.   +10 more
europepmc   +1 more source

A Janus Mucoadhesive and Omniphobic Device for Gastrointestinal Retention

, 2016
Young‐Ah Lucy Lee, Shiyi Zhang, Jiaqi Lin, Róbert Langer, Giovanni Traverso   +4 more
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

In2AB Janus Double-Layered Honeycomb Structures with Nontrivial Topology and Rashba Splitting (A, B = P, As, Sb, or Bi). [PDF]

ACS Omega
D'Souza J, Verzola IMR, Villaos RAB, Maghirang AB, Huang ZQ, Shi Y, Chuang FC.   +6 more
europepmc   +1 more source

Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All

Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

H₂O₂-propelled Janus nanomotor for synergistic treatment of drug-resistant biofilm infections. [PDF]

J Nanobiotechnology
Li D, Yang L, He L, Liu B, Yuan Y, Wang Z, Shi J, Zhang Y.   +7 more
europepmc   +1 more source

Nanoparticles in microdroplets: Recent advances in microfluidic generators for producing functional microbeads

Droplet, EarlyView.
Functional hybrid microbeads with electrical, magnetic, and/or optical responsiveness have emerged as versatile platforms for biotechnology. This review highlights recent advances in microfluidic technologies for producing such microbeads, with a focus on incorporating functional nanoparticles in microdroplet systems.
  Bayinqiaoge, Chengchen Zhang, Shi‐Yang Tang   +2 more
wiley   +1 more source

Theoretical study on the multi-mechanism synergistic bactericidal effect of asymmetric Janus AuNPs-PS microspheres. [PDF]

Nanoscale Adv
He L, Xu H, Yang Y, Chen XB.
europepmc   +1 more source